Compugen Ltd (NASDAQ:CGEN) reported encouraging data from their studies on COM701, COM902, and pembrolizumab in patients with ...

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

The SITC posters will be available on ImCheck's corporate website after the poster sessions have been opened.

Compugen (CGEN) has released an update. Compugen Ltd. has announced promising data on the anti-tumor activity and safety of its triple ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

Ovarian cancer is one of the most deadly cancers; 50 percent of patients die within five years of diagnosis. While ...

Researchers have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study used a ...

New study reveals how ovarian cancer shields itself from the immune system, opening doors to innovative immunotherapy methods ...

Study findings suggest the potential to repurpose a drug that is FDA-approved for treating asthma and eczema, to enhance ...